KarMMa-3 – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 09 Mar 2023 11:31:45 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png KarMMa-3 – VJRegenMed https://mirror.vjregenmed.com 32 32 KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma https://mirror.vjregenmed.com/video/oaqi76v70nw-karmma-3-results-ide-cel-vs-standard-regimens-in-triple-class-exposed-multiple-myeloma/ Thu, 09 Mar 2023 11:31:45 +0000 https://mirror.vjregenmed.com/video/oaqi76v70nw-karmma-3-results-ide-cel-vs-standard-regimens-in-triple-class-exposed-multiple-myeloma/ In this video, Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, gives an overview of the results of the KarMMa-3 study (NCT03651128), a Phase III trial comparing idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple class–exposed relapsed/refractory (R/R) multiple myeloma. The study reported a significant benefit for ide-cel in terms of complete remission (CR) rate and progression-free survival (PFS) across all risk categories. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]>